Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1685

Showing 26-50 of 1685 citing articles:

Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma
Guohe Song, Yang Shi, Meng Lu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 91
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Alessandra Elvevi, Alice Laffusa, Miki Scaravaglio, et al.
Annals of Hepatology (2022) Vol. 27, Iss. 5, pp. 100737-100737
Open Access | Times Cited: 89
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Ainhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 93-108
Open Access | Times Cited: 89
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 87
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 85
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications
Miguel A. Martín-Serrano, Benjamin Kepecs, Miguel Torres‐Martín, et al.
Gut (2022) Vol. 72, Iss. 4, pp. 736-748
Open Access | Times Cited: 84
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities
Tongxin Ge, Xiang Gu, Renbing Jia, et al.
Cancer Communications (2022) Vol. 42, Iss. 11, pp. 1049-1082
Open Access | Times Cited: 83
How I treat biliary tract cancer
Ángela Lamarca, Julien Edeline, Lipika Goyal
ESMO Open (2022) Vol. 7, Iss. 1, pp. 100378-100378
Open Access | Times Cited: 80
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 79
Metabolic reprogramming and its clinical implication for liver cancer
Flora Yang, Leena Hilakivi‐Clarke, Aurpita Shaha, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1602-1624
Open Access | Times Cited: 58
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Bruno Cogliati, Chittampalli Yashaswini, Shuang Wang, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 647-661
Open Access | Times Cited: 53
Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology
Shuyi Ji, Feng Li, Zile Fu, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 706
Closed Access | Times Cited: 52
Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma
Ying Fan, Mandy Sze Man Chan, Terence K. Lee
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 15, Iss. 4, pp. 985-999
Open Access | Times Cited: 48
The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy
Mohamed Bakr Zaki, Ahmed I. Abulsoud, Shereen Saeid Elshaer, et al.
Pathology - Research and Practice (2023) Vol. 245, pp. 154437-154437
Closed Access | Times Cited: 48
Lactate and lactylation in cancer
Jie Chen, Ziyue Huang, Ya Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
“Biological R2” Resection for Intrahepatic Cholangiocarcinoma: Identification of Patients at Risk for Poor Oncologic Outcomes after Curative-Intent Resection
Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, et al.
HPB (2025)
Closed Access | Times Cited: 2
The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma
Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, et al.
Annals of Surgical Oncology (2025)
Open Access | Times Cited: 2
Potential Influence of Antifungal-drug Resistant Pathogens in Patients with Cholangiocarcinoma and the Application of Nanoparticle Mechanisms as Novel Antifungal and Anticancer Agents
Conrad Chibunna Achilonu, Tsepo Ramatla, Maleke Maleke, et al.
Current Clinical Microbiology Reports (2025) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma
Shin‐Yi Chung, Yi‐Chen Yeh, Chien-Jung Huang, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010173-e010173
Open Access | Times Cited: 1
TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy
Tengqian Tang, Wenhao Wang, Li‐Hua Gan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116
Pathogenesis of Cholangiocarcinoma
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, et al.
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 433-463
Open Access | Times Cited: 106
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 4, pp. 343-350
Closed Access | Times Cited: 101
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100354-100354
Open Access | Times Cited: 88
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84

Scroll to top